ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Breast Cancer trials near Rochester, MN, USA:

Niraparib + Dostarlimab in BRCA Mutated Breast Cancer

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PAL...

Enrolling
Breast Cancer
Stage II Breast Cancer
Drug: Niraparib
Drug: Dostarlimab

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Rochester, Minnesota, United States and 8 other locations

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).The Following drugs will be ...

Active, not recruiting
Inflammatory Breast Cancer (IBC)
Drug: Paclitaxel
Drug: Cyclophosphamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Rochester, Minnesota, United States and 3 other locations

This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which...

Active, not recruiting
Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Rochester, Minnesota, United States and 9 other locations

triple negative (TN) or hormone receptor positive/HER2-negative breast cancer.The names of the study interventions involved in this...

Enrolling
Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
Triple Negative Breast Cancer
Drug: Paclitaxel
Drug: Carboplatin

Phase 2

Laura M. Spring, MD

Rochester, Minnesota, United States and 9 other locations

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and whi ...

Enrolling
Male Breast Cancer
Hormone Receptor-positive Breast Cancer
Drug: Tamoxifen
Drug: Anastrozole

Phase 2

Jose Pablo Leone

Rochester, Minnesota, United States and 6 other locations

together. A side effect is anything a drug does besides treating cancer.Participants in this trial have HER2-positive (HER2+) breast...

Active, not recruiting
HER2 Positive Breast Cancer
Drug: trastuzumab deruxtecan
Drug: tucatinib

Phase 2

Seagen
Seagen

Rochester, Minnesota, United States and 32 other locations

to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...

Active, not recruiting
Estrogen Receptor Positive Breast Cancer
HER-2 Positive Breast Cancer
Drug: palbociclib
Drug: trastuzumab

Phase 3

Alliance Foundation Trials

Rochester, Minnesota, United States and 117 other locations

with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two pr...

Enrolling
Hormone Receptor Positive HER-2 Negative Breast Cancer
Metastatic Breast Cancer
Drug: Alisertib
Drug: Endocrine therapy

Phase 2

Puma Biotechnology
Puma Biotechnology

Rochester, Minnesota, United States and 11 other locations

postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have diseas...

Active, not recruiting
Locally Advanced or Metastatic Breast Cancer
Drug: Lasofoxifene
Drug: Fulvestrant

Phase 2

Sermonix Pharmaceuticals

Rochester, Minnesota, United States and 50 other locations

The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers ...

Enrolling
HER2 Positive Breast Carcinoma
Metastatic Breast Cancer
Drug: Trastuzumab
Drug: Niraparib

Phase 1, Phase 2

The University of Alabama at Birmingham
The University of Alabama at Birmingham

Rochester, Minnesota, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems